Leading Edge Care

Regenerative medicine, also called orthobiologic therapy, works to improve the healing of injured muscles, tendons and joints. The hope is that these treatments can offer relief at a level between a more minor cartilage repair procedure and full joint replacement.

The body has a strong ability to heal itself. Two cell factors, MSCs and platelets, assist in tissue restoration and regeneration.

These cellular substances may:

MSCs, previously known as Mesenchymal stem cells, and PRP (platelet-rich plasma) are considered biologic therapy. These substances are derived from the body and are injected into the injured or diseased area, such as an injured muscle, an inflamed tendon or an arthritic joint.

Platelet rich plasma, or PRP, comes from your blood. Platelets are cells in your blood that have a lot of growth factors and anti-inflammatory agents, both of which help your body to heal.

If your body is injured, platelets are naturally delivered to the injury. The platelets will then release the substances that they hold that help encourage tissue repair. Almost all tissue injuries heal using this process.

For PRP, a sample of your blood is taken. The sample is processed to concentrate the platelets together into the plasma (a layer of your blood), which is then injected into the part of your body that needs healing. The procedure is done in an office and takes 20-30 minutes. Talk with your physician about any activities that you shouldnt do after the procedure.

MSCs can turn into multiple types of cells and tissues. If you break a bone, for example, you will need more bone cells in order to heal the fracture. MSCs are sent by your body to the fracture and grow into new bone cells to repair the break. The same process occurs if you tear a muscle or have a cut in your skin. The description is simple, but the actual process within your body is incredibly complicated.

Mesenchymal stem cells are a specific type of cell in your body. They line blood vessels, and the type used for orthobiologic injection therapy can most easily be found in bone marrow, fat, and amniotic fluid. When injected into an injured or diseased joint or tissue, they dont turn into other types of cells. Instead, they send out signals to the body to decrease inflammation, pain, and infection.

To receive MSC therapy, you will go to an office or to a procedure center.

Amniotic products are shipped frozen, thawed just before use, and are injected into the part of the body being treated.

Bone marrow products and adipose-derived (fat-derived) MSCs are taken from your body: bone marrow MSCs from the crest of your pelvic bone and adipose-derived MSCs from your belly or flank. In both cases the area is anesthetized (numbed) and a needle is placed to draw out the tissue.

The bone marrow or adipose tissue is processed to concentrate important cells and factors which are then injected into the part of the body being treated.

Adipose,or fat tissue, gives the highest amount of cells for these purposes that we know of.

Q: Which are better: PRP or MSCs?A: We dont have this answer. Research has shown that both procedures are generally effective regarding accelerated tendon healing and joint pain control.

Q: How many injections are required?A: Scientists are still studying this. Most MSC studies published used a single injection. Many PRP studies are use several injections separated by weeks or a month. Evidence has not shown for certain that multiple injections are better than a single injection yet.

Q: If I have MSCs injected into my arthritic knee, will it grow new cartilage?A: Studies have shown that areas with cartilage damage may heal better when MSCs are injected. However, the effect of orthobiologic injections is thought to be more pain control than regrowing cartilage. In a knee with arthritis, orthobiologic therapy is a potential bridge between knee restoration and a total knee replacement. You can, however, achieve significant pain control for a period of time. If you have a bone-on-bone joint, where all of the cartilage has worn away, it is very unlikely that an injection with MSCs will give you a new layer of cartilage.

Q: How long will the injection last?A: Studies have shown that the pain-controlling effects of some orthobiologic injections may last 1-2 years or longer. However, PRP studies mostly look at 6-12 month follow-up.

Q: How fast will the injection work?A: While the cells go to work immediately, the effects can take 1-2 months before you notice results. The exact amount of time varies by patient and depends on the exact amount and type of damage being treated.

Q: Which MSC preparation is best: BMAC, adipose, or amniotic?A: Scientists are still working to figure this out. For example, PRP has very effective growth factors, cytokines, and proteins, and few if any cells. Fat and bone marrow have more cells, but were not sure yet if more cells means it will work better.

Q: What does research show?A: Orthobiologic products are a hot button concept in medicine today. Orthobiologics are regularly being used in orthopedics, although we do not fully understand their definition or efficacy. However, scientific studies show good pain relief for people with arthritis and some types of tendon problems, plus quicker healing of tendon injuries with PRP and some MSC products. It could be years before we have all the answers.

Q: Are orthobiologic injections covered by insurance? How much does it cost?A: Currently most insurance policies do not cover orthobiologic injections since they are considered investigational. Speak to your physicians office about the price, which varies depending on the product and procedure used. Ask your health savings account advisor to see if these injections qualify.

Q: How do I make an appointment?A: First, you need to have a screening appointment to see if youre a candidate for these orthobiologic injections. The screening appointment may involve x-rays and an MRI. The physician will then determine if orthobiologic injections are right for you. A separate appointment will be scheduled for the actual procedure.

Excerpt from:
Regenerative Medicine | OrthoVirginia

At Mayo Clinic, an integrated team, including stem cell biologists, bioengineers, doctors and scientists, work together and study regenerative medicine. The goal of the team is to treat diseases using novel therapies, such as stem cell therapy and bioengineering. Doctors in transplant medicine and transplant surgery have pioneered the study of regenerative medicine during the past five decades, and doctors continue to study new innovations in transplant medicine and surgery.

In stem cell therapy, or regenerative medicine, researchers study how stem cells may be used to replace, repair, reprogram or renew your diseased cells. Stem cells are able to grow and develop into many different types of cells in your body. Stem cell therapy may use adult cells that have been genetically reprogrammed in the laboratory (induced pluripotent stem cells), your own adult stem cells that have been reprogrammed or developed.

Researchers also study and test how reprogrammed stem cells may be turned into specialized cells that can repair or regenerate cells in your heart, blood, nerves and other parts of your body. These stem cells have the potential to treat many conditions. Stem cells also may be studied to understand how other conditions occur, to develop and test new medications, and for other research.

Researchers across Mayo Clinic, with coordination through the Center for Regenerative Medicine, are discovering, translating and applying stem cell therapy as a potential treatment for cardiovascular diseases, diabetes, degenerative joint conditions, brain and nervous system (neurological) conditions, such as Parkinson's disease, and many other conditions. For example, researchers are studying the possibility of using stem cell therapy to repair or regenerate injured heart tissue to treat many types of cardiovascular diseases, from adult acquired disorders to congenital diseases. Read about regenerative medicine research for hypoplastic left heart syndrome.

Cardiovascular diseases, neurological conditions and diabetes have been extensively studied in stem cell therapy research. They've been studied because the stem cells affected in these conditions have been the same cell types that have been generated in the laboratory from various types of stem cells. Thus, translating stem cell therapy to a potential treatment for people with these conditions may be a realistic goal for the future of transplant medicine and surgery.

Researchers conduct ongoing studies in stem cell therapy. However, research and development of stem cell therapy is unpredictable and depends on many factors, including regulatory guidelines, funding sources and recent successes in stem cell therapy. Mayo Clinic researchers aim to expand research and development of stem cell therapy in the future, while keeping the safety of patients as their primary concern.

Mayo Clinic offers stem cell transplant (bone marrow transplant) for people who've had leukemia, lymphoma or other conditions that have been treated with chemotherapy.

Visit link:
Mayo Clinic Transplant Center - Regenerative medicine

Sanford Health a history of innovating and leading the way in new research.

Something that grabbed the attention of the NFL Alumni Association.

The NFL Alumni Association is a non-profit that looks to support retired NFL athletes and cheerleaders after their initial careers are over.

Because of the strenuous activity put on their bodies, many athletes walk away from the sport with nagging injuries without the option for care. This has led the NFL Alumni to seek out innovators in the world of health care.

Recently, Dr. David Pearce, Sanford Health president for innovation, research and World Clinic, spoke on regenerative medicine at a congressional briefing. His expertise prompted Kyle Richardson and Billy Davis, co-directors of health care initiatives for the NFL Alumni Association, to inquire about regenerative medicine and how it may serve retired athletes.

More: NFL Alumni tour Sanford, discuss regenerative medicine

As Dr. Pearce told Sanford Health News, its a complicated term, but regenerative medicine is essentially about healing. Dr. Pearce explains that regenerative healing takes something from your own body to heal a wound or an injury.

Im going to give you an example: if you cut yourself right now, it heals, right? The components within your body have the ability to heal an injury, such as a cut. If we twist our ankle and we get swelling, our body reacts and heals that injury. Regenerative medicine is about accelerating that healing so, taking a component of your body, and accelerating that healing and making it better.

Not only for retired athletes, this form of therapy could benefit everyone as they age.

As we get older, we start to deteriorate. So, we can harness our own body to maybe take some of those components that would be used to fix an injury to actually slow down the aging process and the wear and tear on joints, partiucularly in orthopedics.

Thats one of the highlighted areas that we are studying right now. As your knees grind away and you get arthritis, regenerative medicine is about taking some of those healing components to help regenerate and slow down that process, to heal those aches and pains, said Dr. Pearce.

Tiffany Facile is a research development partner at Sanford Health, and soon-to-be director of regenerative medicine at Sanford Health.

She says its imperative this medicine develops through the science of clinical trials.

Some common misconceptions are that regenerative medicine therapies are risky. There is some risk to procedures when using autologous or your own cells, but studies that are currently running should reduce the safety concerns.

Dr. Pearce echos Facile, warning of bad actors who offer products which have no regenerative capacity.

He says theres also a misconception associated with these therapies because theyre not approved by the FDA. However, Sanford Healths clinical trials have been approved.

What were doing at Sanford, is were taking those components of the body, working with the FDA and saying, its safe to do this. Our early work in a clinical study has demonstrated safety and efficacy with rotator cuff injuries. Were having remarkable results in terms of treating some of these injuries.

Another misconception revolves around stem cells. Both Facile and Dr. Pearce say regenerative medicine has not yet determined if stem cells in your body have the ability to signal other cells for repair.

We hear about embryonic stem cells and fetal stem cells; we dont do anything with that. First of all, its not very ethical. Secondly, theres no science to show that they can have regenerative capabilities, said Dr. Pearce.

Dr. Pearce says regenerative medicine can be used to heal nagging injuries, whether its for athletes or not.

Right now were taking cells from around the fat of your abdomen region, which is rich in a type of stem cell called adipose derived regenerative cells, and were relocating them to help heal rotator cuff tears, help to heal osteoarthritis in the knee, elbow, wrist, ankle, and hip, he said.

Dr. Pearce says theyre doing this research, under the auspices of what we call a clinical trial, and where we follow patients to hopefully demonstrate safety and efficacy.

Because of the misconceptions surrounding this form of medicine, we have to do this right, because its not a regulated industry just yet. The food and drug administration oversees what were doing with respect to that.

We know that we can help heal damaged heart cells. We know we can help healing cells that have been damaged by a stroke. Were already taking the next step in working on those protocols where we can do some trials and look to see if we can heal other injuries in the body. These cells have the ability to heal anything in the body, if directed in the right way, said Dr. Pearce.

Dr. Pearce says Sanford Health is the first health system in the nation to get approval for the use of regenerative medicine in treating orthopedic injuries.

Were hoping to be a leader not just in the Midwest, were hoping to be a leader nationally, where we can teach other health systems how to administer these treatments by either going there and training people, or us becoming really a hub for that.

As for the future of regenerative medicine, Dr. Pearce says it could have an impact in how quickly athletes recover from injuries.

I think for athletes that return to play, this will have a huge impact in terms of how we can help people turn around. More importantly, as they retire, we know theres a lot of grinding and wear and tear on their bodies. Well be able to manage that much more appropriately, said Dr. Pearce.

This form of medicine can also help non-athletes manage any nagging aches and pains.

For those whove got some aches and pains here and there, well be able to use this to really alleviate some of the pain and aches we have, and manage that much better.

Posted In Innovations, Orthopedics, Research, Specialty Care, Sports Medicine, World Clinic

See the original post:
What is regenerative medicine? - Sanford Health News

Full Article

Regenerative medicine, the application of treatments developed to replace tissues damaged by injury or disease. These treatments may involve the use of biochemical techniques to induce tissue regeneration directly at the site of damage or the use of transplantation techniques employing differentiated cells or stem cells, either alone or as part of a bioartificial tissue. Bioartificial tissues are made by seeding cells onto natural or biomimetic scaffolds (see tissue engineering). Natural scaffolds are the total extracellular matrixes (ECMs) of decellularized tissues or organs. In contrast, biomimetic scaffolds may be composed of natural materials, such as collagen or proteoglycans (proteins with long chains of carbohydrate), or built from artificial materials, such as metals, ceramics, or polyester polymers. Cells used for transplants and bioartificial tissues are almost always autogeneic (self) to avoid rejection by the patients immune system. The use of allogeneic (nonself) cells carries a high risk of immune rejection and therefore requires tissue matching between donor and recipient and involves the administration of immunosuppressive drugs.

A variety of autogeneic and allogeneic cell and bioartificial tissue transplantations have been performed. Examples of autogeneic transplants using differentiated cells include blood transfusion with frozen stores of the patients own blood and repair of the articular cartilage of the knee with the patients own articular chondrocytes (cartilage cells) that have been expanded in vitro (amplified in number using cell culture techniques in a laboratory). An example of a tissue that has been generated for autogeneic transplant is the human mandible (lower jaw). Functional bioartificial mandibles are made by seeding autogeneic bone marrow cells onto a titanium mesh scaffold loaded with bovine bone matrix, a type of extracellular matrix that has proved valuable in regenerative medicine for its ability to promote cell adhesion and proliferation in transplantable bone tissues. Functional bioartificial bladders also have been successfully implanted into patients. Bioartificial bladders are made by seeding a biodegradable polyester scaffold with autogeneic urinary epithelial cells and smooth muscle cells.

Another example of a tissue used successfully in an autogeneic transplant is a bioartificial bronchus, which was generated to replace damaged tissue in a patient affected by tuberculosis. The bioartificial bronchus was constructed from an ECM scaffold of a section of bronchial tissue taken from a donor cadaver. Differentiated epithelial cells isolated from the patient and chondrocytes derived from mesenchymal stem cells collected from the patients bone marrow were seeded onto the scaffold.

There are few clinical examples of allogeneic cell and bioartificial tissue transplants. The two most common allogeneic transplants are blood-group-matched blood transfusion and bone marrow transplant. Allogeneic bone marrow transplants are often performed following high-dose chemotherapy, which is used to destroy all the cells in the hematopoietic system in order to ensure that all cancer-causing cells are killed. (The hematopoietic system is contained within the bone marrow and is responsible for generating all the cells of the blood and immune system.) This type of bone marrow transplant is associated with a high risk of graft-versus-host disease, in which the donor marrow cells attack the recipients tissues. Another type of allogeneic transplant involves the islets of Langerhans, which contain the insulin-producing cells of the body. This type of tissue can be transplanted from cadavers to patients with diabetes mellitus, but recipients require immunosuppression therapy to survive.

Cell transplant experiments with paralyzed mice, pigs, and nonhuman primates demonstrated that Schwann cells (the myelin-producing cells that insulate nerve axons) injected into acutely injured spinal cord tissue could restore about 70 percent of the tissues functional capacity, thereby partially reversing paralysis.

Studies on experimental animals are aimed at understanding ways in which autogeneic or allogeneic adult stem cells can be used to regenerate damaged cardiovascular, neural, and musculoskeletal tissues in humans. Among adult stem cells that have shown promise in this area are satellite cells, which occur in skeletal muscle fibres in animals and humans. When injected into mice affected by dystrophy, a condition characterized by the progressive degeneration of muscle tissue, satellite cells stimulate the regeneration of normal muscle fibres. Ulcerative colitis in mice was treated successfully with intestinal organoids (organlike tissues) derived from adult stem cells of the large intestine. When introduced into the colon, the organoids attached to damaged tissue and generated a normal-appearing intestinal lining.

In many cases, however, adult stem cells such as satellite cells have not been easily harvested from their native tissues, and they have been difficult to culture in the laboratory. In contrast, embryonic stem cells (ESCs) can be harvested once and cultured indefinitely. Moreover, ESCs are pluripotent, meaning that they can be directed to differentiate into any cell type, which makes them an ideal cell source for regenerative medicine.

Studies of animal ESC derivatives have demonstrated that these cells are capable of regenerating tissues of the central nervous system, heart, skeletal muscle, and pancreas. Derivatives of human ESCs used in animal models have produced similar results. For example, cardiac stem cells from heart-failure patients were engineered to express a protein (Pim-1) that promotes cell survival and proliferation. When these cells were injected into mice that had experienced myocardial infarction (heart attack), the cells were found to enhance the repair of injured heart muscle tissue. Likewise, heart muscle cells (cardiomyocytes) derived from human ESCs improved the function of injured heart muscle tissue in guinea pigs.

Derivatives of human ESCs are likely to produce similar results in humans, although these cells have not been used clinically and could be subject to immune rejection by recipients. The question of immune rejection was bypassed by the discovery in 2007 that adult somatic cells (e.g., skin and liver cells) can be converted to ESCs. This is accomplished by transfecting (infecting) the adult cells with viral vectors carrying genes that encode transcription factor proteins capable of reprogramming the adult cells into pluripotent stem cells. Examples of these factors include Oct-4 (octamer 4), Sox-2 (sex-determining region Y box 2), Klf-4 (Kruppel-like factor 4), and Nanog. Reprogrammed adult cells, known as induced pluripotent stem (iPS) cells, are potential autogeneic sources for cell transplantation and bioartificial tissue construction. Such cells have since been created from the skin cells of patients suffering from amyotrophic lateral sclerosis (ALS) and Alzheimer disease and have been used as human models for the exploration of disease mechanisms and the screening of potential new drugs. In one such model, neurons derived from human iPS cells were shown to promote recovery of stroke-damaged brain tissue in mice and rats, and, in another, cardiomyocytes derived from human iPS cells successfully integrated into damaged heart tissue following their injection into rat hearts. These successes indicated that iPS cells could serve as a cell source for tissue regeneration or bioartificial tissue construction.

More here:
regenerative medicine | Definition, Stem Cells, & Facts ...

Regenerative Medicine Market Research Report by Type (Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, and Small Molecule and Biologic), by Application (Diabetes, Musculoskeletal Disorders, and Ocular Disorders), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

New York, July 29, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market Research Report by Type, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06087389/?utm_source=GNW

The Global Regenerative Medicine Market size was estimated at USD 13.95 Billion in 2020 and expected to reach USD 16.69 Billion in 2021, at a Compound Annual Growth Rate (CAGR) 19.94% from 2020 to 2026 to reach USD 41.56 Billion by 2026.

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:This research report categorizes the Regenerative Medicine to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the Regenerative Medicine Market was studied across Cell-Based Immunotherapy & Cell Therapy Products, Gene Therapy Products, Small Molecule and Biologic, and Tissue-Engineered Products. The Cell-Based Immunotherapy & Cell Therapy Products is further studied across Allogeneic Products and Autologous Products.

Based on Application, the Regenerative Medicine Market was studied across Diabetes, Musculoskeletal Disorders, Ocular Disorders, Oncology, Wound Care, and Cardiovascular.

Based on Geography, the Regenerative Medicine Market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific is further studied across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Regenerative Medicine Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Regenerative Medicine Market, including Allergan plc, Amgen Inc., Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Medtronic Plc, Mimedx Group, Novartis AG, Organogenesis Inc., Osiris Therapeutics, Inc., Smith & Nephew plc, Stryker Corporation, Takeda Pharmaceutical Co. Ltd., Vericel Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings Inc..

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:1. What is the market size and forecast of the Global Regenerative Medicine Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Regenerative Medicine Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Regenerative Medicine Market?4. What is the competitive strategic window for opportunities in the Global Regenerative Medicine Market?5. What are the technology trends and regulatory frameworks in the Global Regenerative Medicine Market?6. What is the market share of the leading vendors in the Global Regenerative Medicine Market?7. What modes and strategic moves are considered suitable for entering the Global Regenerative Medicine Market?Read the full report: https://www.reportlinker.com/p06087389/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Excerpt from:
Regenerative Medicine Market Research Report by Type, by Application, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo...

Maharashtra University Of Health Sciences (MUHS), Nashik has been granted first affiliations to conduct a fellowship course in regenerative medicine and stem cell-based therapies on a research basis at Dr Mahajans Hospital & Stem Rx Bioscience Solution, Navi Mumbai. The move will address the education and training gaps in this new area of regenerative medicine.

MD/MS/M.Ch,/DM/DNB qualified surgeons/physicians/super specialists from allopathy, undergraduate or postgraduate degrees equivalent to and recognised by the Medical Council of India are eligible for admission.

Candidates should have six months of basic molecular biological background in basic research. The basic research in molecular biology of human body science is the first time in India to give research background to qualified physicians and surgeons to practice medicine.

The two-year fellowship programme will have FDA regulations, ethics, emerging technologies in stem cell, pre-clinical studies, mesenchymal stem cell isolation and transplantation, etc

Dr Pradeep Mahajan, Regenerative Medicine Researcher, StemRx Bioscience Solutions, Navi Mumbai said, The fellowship course has been designed to ensure that qualified individuals get the required theoretical training as well as practical exposure to learn the intricacies of research in the field of RM. Candidates will be able to pursue their research in this field and contribute to the ever-increasing need for novel therapeutic technologies. It would improve the practice of regenerative and cellular medicine and hopefully obviate the need for regulatory action in some cases.

Original post:
MUHS, Nashik to conduct fellowship course in regenerative medicine - BSI bureau

Newswise Green manufacturing is becoming an increasingly critical process across industries, propelled by a growing awareness of the negative environmental and health impacts associated with traditional practices. In the biomaterials industry, electrospinning is a universal fabrication method used around the world to produce nano- to microscale fibrous meshes that closely resemble native tissue architecture. The process, however, has traditionally used solvents that not only are environmentally hazardous but also pose a significant barrier to industrial scale-up, clinical translation, and, ultimately, widespread use.

Researchers atColumbia Engineeringreport that they have developed a "green electrospinning" process that addresses many of the challenges to scaling up this fabrication method, from managing the environmental risks of volatile solvent storage and disposal at large volumes to meeting health and safety standards during both fabrication and implementation. The teams newstudy, published June 28, 2021, by Biofabrication, details how they have modernized the nanofiber fabrication of widely utilized biological and synthetic polymers (e.g. poly--hydroxyesters, collagen), polymer blends, and polymer-ceramic composites.

The study also underscores the superiority of green manufacturing. The groups green fibers exhibited exceptional mechanical properties and preserved growth factor bioactivity relative to traditional fiber counterparts, which is essential for drug delivery and tissue engineering applications.

Regenerative medicine is a $156 billion global industry, one that is growing exponentially. The team of researchers, led byHelen H. Lu, Percy K. and Vida L.W. Hudson Professor ofBiomedical Engineering, wanted to address the challenge of establishing scalable green manufacturing practices for biomimetic biomaterials and scaffolds used in regenerative medicine.

We think this is a paradigm shift in biofabrication, and will accelerate the translation of scalable biomaterials and biomimetic scaffolds for tissue engineering and regenerative medicine, said Lu, a leader in research on tissue interfaces, particularly the design of biomaterials and therapeutic strategies for recreating the bodys natural synchrony between tissues. Green electrospinning not only preserves the composition, chemistry, architecture, and biocompatibility of traditionally electrospun fibers, but it also improves their mechanical properties by doubling the ductility of traditional fibers without compromising yield or ultimate tensile strength. Our work provides both a more biocompatible and sustainable solution for scalable nanomaterial fabrication.

The team, which included several BME doctoral students from Lus group, Christopher Mosher PhD20 and Philip Brudnicki, as well as Theanne Schiros, an expert in eco-conscious textile synthesis who is also a research scientist at Columbia MRSEC and assistant professor at FIT, applied sustainability principles to biomaterial production, and developed a green electrospinning process by systematically testing what the FDA considers as biologically benign solvents (Q3C Class 3).

They identified acetic acid as a green solvent that exhibits low ecological impact (Sustainable Minds Life Cycle Assessment) and supports a stable electrospinning jet under routine fabrication conditions. By tuning electrospinning parameters, such as needle-plate distance and flow rate, the researchers were able to ameliorate the fabrication of research and industry-standard biomedical polymers, cutting the detrimental manufacturing impacts of the electrospinning process by three to six times.

Green electrospun materials can be used in a broad range of applications. Lus team is currently working on further innovating these materials for orthopaedic and dental applications, and expanding this eco-conscious fabrication process for scalable production of regenerative materials.

"Biofabrication has been referred to as the fourth industrial revolution' following steam engines, electrical power, and the digital age for automating mass production, noted Mosher, the studys first author. This work is an important step towards developing sustainable practices in the next generation of biomaterials manufacturing, which has become paramount amidst the global climate crisis."

###

The study is titled Green electrospinning for biomaterials and biofabrication.

Authors are: Christopher Z. Mosher (A), Philip A.P. Brudnickia (A), Zhengxiang Gonga (A), Hannah R. Childs (A), Sang Won Lee (A),Romare M. Antrobus (A)Elisa C. Fang (A), Theanne N. Schiros (B,C)and Helen H. Lu (A,B)

A. Biomaterials and Interface Tissue Engineering Laboratory, Department of Biomedical Engineering, Columbia University

B. Materials Research Science and Engineering Center, Columbia University

C. Science and Mathematics Department, Fashion Institute of Technology

This work was supported by the National Institutes of Health (NIH-NIAMS 1R01-AR07352901A), the New York State Stem Cell ESSC Board (NYSTEM C029551), the DoD CDMRP award (W81XWH-15- 1-0685), and the National Science Foundation Graduate Research Fellowship (DGE-1644869, CZM). The CD analysis system was supported by NIH grant 1S10OD025102-01, and TNS was supported as part of the NSF MRSEC program through Columbia in the Center for Precision Assembly of Superstratic and Superatomic Solids (DMR-1420634).

The authors declare no competing interest.

Columbia Engineering

Columbia Engineering, based in New York City, is one of the top engineering schools in the U.S. and one of the oldest in the nation. Also known as The Fu Foundation School of Engineering and Applied Science, the School expands knowledge and advances technology through the pioneering research of its more than 220 faculty, while educating undergraduate and graduate students in a collaborative environment to become leaders informed by a firm foundation in engineering. The Schools faculty are at the center of the Universitys cross-disciplinary research, contributing to the Data Science Institute, Earth Institute, Zuckerman Mind Brain Behavior Institute, Precision Medicine Initiative, and the Columbia Nano Initiative. Guided by its strategic vision, Columbia Engineering for Humanity, the School aims to translate ideas into innovations that foster a sustainable, healthy, secure, connected, and creative humanity.

Read more from the original source:
"Greening Biomaterials and Scaffolds Used in Regenerative Medicine - Newswise

The organ of Corti, the hearing organ of the inner ear, contains rows of sensory hearing cells (green) surrounded by supporting cells (blue). Credit: Image by Yassan Abdolazimi/Segil Lab/USC Stem Cell

Scientists from the USC Stem Cell laboratory of Neil Segil have identified a natural barrier to the regeneration of the inner ears sensory cells, which are lost in hearing and balance disorders. Overcoming this barrier may be a first step in returning inner ear cells to a newborn-like state thats primed for regeneration, as described in a new study published inDevelopmental Cell.

Permanent hearing loss affects more than 60 percent of the population that reaches retirement age, said Segil, who is a Professor in the Department of Stem Cell Biology and Regenerative Medicine, and the USC Tina and Rick Caruso Department of Otolaryngology Head and Neck Surgery. Our study suggests new gene engineering approaches that could be used to channel some of the same regenerative capability present in embryonic inner ear cells.

In the inner ear, the hearing organ, which is the cochlea, contains two major types of sensory cells: hair cells that have hair-like cellular projections that receive sound vibrations; and so-called supporting cells that play important structural and functional roles.

When the delicate hair cells incur damage from loud noises, certain prescription drugs, or other harmful agents, the resulting hearing loss is permanent in older mammals. However, for the first few days of life, lab mice retain an ability for supporting cells to transform into hair cells through a process known as transdifferentiation, allowing recovery from hearing loss. By one week of age, mice lose this regenerative capacityalso lost in humans, probably before birth.

Based on these observations, postdoctoral scholar Litao Tao, PhD, graduate student Haoze (Vincent) Yu, and their colleagues took a closer look at neonatal changes that cause supporting cells to lose their potential for transdifferentiation.

In supporting cells, the hundreds of genes that instruct transdifferentiation into hair cells are normally turned off. To turn genes on and off, the body relies on activating and repressive molecules that decorate the proteins known as histones.In response to these decorations known as epigenetic modifications, the histone proteins wrap the DNA into each cell nucleus, controlling which genes are turned on by being loosely wrapped and accessible, and which are turned off by being tightly wrapped and inaccessible. In this way, epigenetic modifications regulate gene activity and control the emergent properties of the genome.

In the supporting cells of the newborn mouse cochlea, the scientists found that hair cell genes were suppressed by both the lack of an activating molecule, H3K27ac, and the presence of the repressive molecule, H3K27me3.However, at the same time, in the newborn mouse supporting cells, the hair cell genes were kept primed to activate by the presence of yet a different histone decoration, H3K4me1.During transdifferentiation of a supporting cell to a hair cell, the presence of H3K4me1 is crucial to activate the correct genes for hair cell development.

Unfortunately with age, the supporting cells of the cochlea gradually lost H3K4me1, causing them to exit the primed state. However, if the scientists added a drug to prevent the loss of H3K4me1, the supporting cells remained temporarily primed for transdifferentiation. Likewise, supporting cells from the vestibular system, which naturally maintained H3K4me1, were still primed for transdifferentiation into adulthood.

Our study raises the possibility of using therapeutic drugs, gene editing, or other strategies to make epigenetic modifications that tap into the latent regenerative capacity of inner ear cells as a way to restore hearing, said Segil. Similar epigenetic modifications may also prove useful in other non-regenerating tissues, such as the retina, kidney, lung, and heart.

Reference: Enhancer decommissioning imposes an epigenetic barrier to sensory hair cell regeneration by Litao Tao, Haoze V. Yu, Juan Llamas, Talon Trecek, Xizi Wang, Zlatka Stojanova, Andrew K. Groves and Neil Segil, 30 July 2021, Developmental Cell.DOI: 10.1016/j.devcel.2021.07.003

Additional co-authors of the study include Juan Llamas, Talon Trecek, Xizi Wang, andZlatka Stojanovain the Segil Lab at USC, and Andrew K. Groves at Baylor College of Medicine.

Sixty percent of this project was supported by federal funding from the National Institute on Deafness and Other Communication Disorders (R01DC015829, R01DC014832, T32DC009975, F31DC017376). Additional funding came from the Hearing Restoration Project at the Hearing Health Foundation.

See the original post here:
Stem Cell Scientists Explore the Latent Regenerative Potential of the Inner Ear - SciTechDaily

STONY BROOK AND ROCKVILLE CENTRE, NY August 4, 2021 Stony Brook Medicine (SBM) and Catholic Health (CH) have signed a letter of intent to explore a collaboration that would expand leading-edge academic medicine and advanced clinical care and deliver greater health care options to Long Islanders.

This potential collaboration will improve patient care, offer new services and enhance medical education for both systems, said Catholic Health President & Chief Executive Officer Patrick M. OShaughnessy, DO, MBA. There will be additional options for physicians and high quality, high value services for all Long Islanders.

This relationship will include the development of an integrated strategic and clinical plan to grow and align trauma services, pediatric capabilities, clinical service lines and training opportunities for medical residents in the health care systems and for students in Stony Brook Universitys Renaissance School of Medicine, added Margaret M. McGovern, MD, PhD, Dean for Clinical Affairs, Renaissance School of Medicine at Stony Brook University and Vice President, Health System Clinical Programs and Strategy, Stony Brook Medicine. By expanding training options, we will enable a more robust learning experience and lead to a talented, well prepared and persistent stream of incoming practitioners serving our Long Island communities.

The proposed relationship affords the two health systems a unique opportunity to work together on key initiatives while remaining separate and independent in all other respects. Other projects may include population health initiatives and further options for care coordination.

This collaboration is a natural outcome of the synergies of both organizations longstanding reputation for excellence in the community, state-of-the-art facilities and services, leading-edge technology and increasing focus on academic excellence and expanding clinical research opportunities.

About Stony Brook Medicine:

Stony Brook Medicine encompasses all of Stony Brook Universitys health-related initiatives: education, research and patient care. It includes five Health Sciences schools Dental Medicine, Health Technology and Management, Renaissance School of Medicine, Nursing and Social Welfare as well as Stony Brook University Hospital, Stony Brook Southampton Hospital, Stony Brook Eastern Long Island Hospital, Stony Brook Childrens Hospital and more than 200 community-based healthcare settings throughout Suffolk County. To learn more, visitstonybrookmedicine.edu.

About Stony Brook University Hospital:

Stony Brook University Hospital (SBUH) is Long Islands premier academic medical center. With 624 beds, SBUH serves as the regions only tertiary care center and Regional Trauma Center, and is home to the Stony Brook University Heart Institute, Stony Brook University Cancer Center, Stony Brook Childrens Hospital and Stony Brook University Neurosciences Institute. SBUH also encompasses Suffolk Countys only Level 4 Regional Perinatal Center, state-designated AIDS Center, state-designated Comprehensive Psychiatric Emergency Program, state-designated Burn Center, the Christopher Pendergast ALS Center of Excellence, and Kidney Transplant Center. It is home of the nations first Pediatric Multiple Sclerosis Center. To learn more, visitstonybrookmedicine.edu/sbuh.

About the Renaissance School of Medicine at Stony Brook University:

Established in 1971, Renaissance School of Medicine at Stony Brook University includes 25 academic departments. The three missions of the School are to advance the understanding of the origins of human health and disease; train the next generation of committed, curious and highly capable physicians; and deliver world-class compassionate healthcare. As a member of the Association of American Medical Colleges (AAMC) and a Liaison Committee on Medical Education (LCME) accredited medical school, Stony Brook is one of the foremost institutes of higher medical education in the country. Each year the School trains over 600 medical students and more than 750 medical residents and fellows. Faculty research includes National Institutes of Health-sponsored programs in neurological diseases, cancer, cardiovascular disorders, biomedical imaging, regenerative medicine, infectious diseases, and many other topics. Physicians on the School of Medicine faculty deliver world-class medical care through more than 31,000 inpatient, 104,000 emergency room and 1 million outpatient visits annually at Stony Brook University Hospital and affiliated clinical programs, making its clinical services one of the largest and highest quality medical schools on Long Island, New York. To learn more, visitrenaissance.stonybrookmedicine.edu.

About Catholic Health:

With approximately 17,000 employees, Catholic Health is an integrated system serving Long Islands many communities. With more than 4,600 medical staff and 4,000 nurses, the health system has an extensive network of ambulatory care locations and physician practices, 6 hospitals and a continuing care division encompassing skilled nursing and rehabilitation, home nursing and hospice care. Under the sponsorship of the Diocese of Rockville Centre, Catholic Health provides services that extend from the beginning of life to helping people live their final years in comfort, grace and dignity.

Combined, St. Francis Hospital & Heart Center, Good Samaritan Hospital, Mercy Hospital, St. Charles Hospital, St. Catherine of Siena Hospital and St. Joseph Hospital have more than 1,900 certified hospital beds, and the health system also has 685 nursing home beds. Catholic Health Physician Partners has more than 450 employed providers in approximately 90 locations across Nassau and Suffolk counties.

Catholic Health excels in cardiac services, with St. Francis Hospital & Heart Center being nationally ranked byU.S. News & World Reportfor Cardiology & Heart Surgery (20202021)more times than any other hospital in the region in this specialty. St. Francis Heart Center services are available in both Nassau and Suffolk. Additionally, the health care system is widely recognized for oncology services, and its cancer institute has four locations across the Island.

Good Samaritan is one of just seven hospitals nationwide to receive the Outstanding Achievement Award from the American College of Surgeons (ACS) Commission on Cancer for 18 consecutive years. It is also the only ACS-Verified Level 2 Trauma Center for both adults and pediatrics on the south shore of Long Island.

All six Catholic Health hospitals are designated stroke centers and have received the Get With The Guidelines Stroke Gold Plus Quality Achievement Award from the American Stroke Association. Also, they have each earned The Joint Commissions Gold Seal of Approval and are fully accredited.To learn more, please seeAwards and Recognition | CHSLI.

For a quarter of a century, Catholic Healths Good Samaritan Hospital (GSH) has attracted numerous medical graduates to its residency programs because of its stellar reputation across a number of medical specialties, many involving complex care and treatment. These programs include emergency medicine, family medicine, pediatrics, podiatric surgery and OB/GYN, as well as fellowship training programs in pediatric emergency medicine and minimally invasive gynecologic surgery. As part of Catholic Health, a patient-focused health care system, students/residents who complete their training at GSH have a number of worthwhile career paths to consider across our six hospitals and a large number of employed practices.

Read the original:
Stony Brook Medicine and Catholic Health Discuss Collaboration; Expanding Health Care Options for Long Islanders | | SBU News - Stony Brook News

The next major development in Israels life science industry is coming from a microscopic source. Biotech based on the tiny building blocks of life is a sector positioned to unlock new discoveries and drive economic growth in the future.

Although the Start-Up Nation is a well-deserved nickname, I believe Biotech Nation will soon be a better fit.

Biotechnology accounts for more than one-quarter of the countrys life science scene. There are currently 468 active biotech firms, employing thousands of high-skilled workers.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

And the industry is evolving in new directions.

We are amid a bio-convergence revolution. This means that biology research increasingly leverages multidisciplinary talent, such as computer engineers, big data scientists, artificial intelligence and advanced manufacturing.

The results are broader capabilities, bolder aspirations and bigger breakthroughs. IATI views bio-convergence as the next major economic growth engine for Israel.

The government is also betting on bio-convergence.

Since the Israel Innovation Authority launched CRISPR-IL, a consortium that combines artificial intelligence and CRISPR capabilities to develop genome editing tools, our leading scientists and biotech companies are joining forces to find new treatments and cures.

I am proud Pluristem is teaming up with this initiative. Partnerships like CRISPR-IL are setting an exemplary model that will lead to many more industry disruptions.

It should come as no surprise that when compared to the rest of the world, Israel spends the highest percentage of GDP on research and development. We already have 300 research groups and 30 academic centers working on bio-convergence R&D.

I have observed that in the wake of the COVID-19 pandemic, interest in regenerative medicine research skyrocketed. At Pluristem, we are developing cell-based therapeutics derived from donated placentas to potentially treat hematological deficiencies, radiation exposure, and muscle injuries related to hip fracture surgery.

Now, there are more 1,000 regenerative medicine trials active around the world. The Alliance for Regenerative Medicine reports that about 85% are in Phase I or II studies. Pluristem has one of the few in Phase III: our PLX-PAD product candidate to support muscle regeneration following hip fracture surgery may be the first approved treatment of its kind.

Early on, we knew that it would also be critical to have our own proprietary cell manufacturing technology that could be scalable from research to commercial use. So, we developed a three-dimensional micro-environment mimicking the conditions in the human body, which allows us to expand our placenta cells and transform them to cell therapy products. This result is only made possible by a cross section of talent from clinical and technology backgrounds, demonstrating the power of bio-convergence.

Its not a moment too soon. Most countries face demographic headwinds, such as aging and declining populations. Many developed nations are already experiencing these trends coupled with skyrocketing health care costs. The world will see a surge in demand for new treatments and ways to control healthcare spending.

The Israeli approach, leveraging out-of-the-box thinking, a spirit of innovation, and a long track record of breakthrough treatments, can convert these challenges into opportunities.

Technology is a force that brings people together, across professional fields, cultures, and borders. When advanced technology is paired with cutting edge medical research, we have the power to craft the future we want.

As IATI reports, our biotech sector is full of boundless opportunities. Israel is one of the greatest places in the world for biotech companies to thrive.

The writer is CEO and president of Pluristem. He is also a board member and former co-chairman of Israel Advanced Technology Industries, and served as CFO of Elbit Vision Systems.

The rest is here:
Israel: The 'Start-Up Nation' is now the 'Biotech Nation' - opinion - The Jerusalem Post